The impact of treatment on the risk of second malignancy after Hodgkin's disease

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1727-1729

  Ng, A K ^a   Mauch, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; DRUG MEGADOSE; EATING HABIT; EDITORIAL; FOLLOW UP; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; LEUKEMIA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SECOND CANCER; SOLID TUMOR; SUN EXPOSURE; SYSTEMATIC REVIEW; TOBACCO;

HODGKIN DISEASE; HUMANS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 33845350199     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl433     Document Type: Editorial

References (26)

1. Ries L, Harkins D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2003/. (November 2005, date last accessed).
2. Arseneau JC, Sponzo RW, Levin DL et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med 1972; 287: 1119-1122.
3. Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-2108.
4. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
5. Biti G, Cellai E, Magrini SM et al. Second solid tumors and leukemia after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994; 29: 25-31.
6. Cellai E, Magrini SM, Masala G et al. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 2001; 49: 1327-1337.
7. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's disease. Ann Oncol 1992; 3 (Suppl 4): 117-128.
8. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996.
9. Swerdlow AJ, Barber JA, Hudson GV et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 2000; 18: 498-509.
10. van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-497.
11. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182-192.
12. Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003; 290: 465-475.
13. van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 971-980.
14. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
15. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
16. Aleman BM, Raemaekers JM, Tirelli U et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-2406.
17. Bonadonna G, Bonfante V, Viviani S et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835-2841.
18. Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-3489.
19. Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-4642.
20. Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-3135.
21. Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment for Hodgkin lymphoma: Meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749-1760.
22. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med 2001; 1: 478-484.
23. Mullen PD, Ramirez G. The promise and pitfalls of systematic reviews. Annu Rev Public Health 2006; 27: 81-102.
24. Nanchman JB, Sposto R, Herzog P et al. Randomised comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771.
25. Laskar S, Gupta T, Vimal S et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004; 22: 62-68.
26. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.